A strong Module 3 is clear, consistent and built alongside development – not written at the end. It should explain what the product is, how it is manufactured, and why the proposed control strategy is appropriate – without unnecessary detail that creates future constraints.
Module 3 is the quality part of the Common Technical Document (CTD) used in marketing authorisation applications for medicinal products. It describes how the product is made and controlled, and it remains the reference throughout the product lifecycle.
In practice, this is often the part of the dossier where problems appear. The issue is rarely missing data alone, but how that data is structured, justified and kept consistent across the dossier. The points below focus on what makes Module 3 work in practice, based on hands-on experience from submissions and lifecycle work. The same principles apply to veterinary medicinal products’ Part 2, even if some details differ.
Define roles and ownership for Module 3 early
A strong Module 3 is never written by one function alone. At minimum, it requires close collaboration between CMC, Regulatory Affairs and Quality Assurance. Each brings a different perspective: CMC provides the scientific and technical substance, Regulatory Affairs ensures alignment with current expectations and dossier strategy, and QA anchors the content in GMP reality and lifecycle compliance.
Equally important is how this collaboration is organised over time. Module 3 does not come from a single writing phase but develops through planned iterations that follow the maturity of data and decisions. Early drafts focus on structure and scope, later versions on justification, consistency and regulatory precision. When this progression is clear, rewriting becomes purposeful rather than reactive.
A named Module 3 owner ensures that inputs from different functions come together into one consistent dossier. Typically Module 3 owner is on the CMC regulatory expert. This role is not about writing every section, but about maintaining the overall logic: making sure changes in one area are reflected elsewhere, that commitments remain appropriate, and that the dossier evolves in line with development.
Without defined ownership, Module 3 often breaks into function-specific texts. With ownership, iteration stays controlled, responsibilities are clear, and the dossier gradually becomes a stable, defensible whole.
Make the control strategy clear
Good Module 3 tells a clear and consistent story about how quality is built into the product. Assessors should be able to quickly understand:
- What is the product
- How is the product manufactured
- How are critical quality attributes controlled
- Why is the proposed control strategy appropriate and robust
This requires more than technical completeness. It requires structure, logic, and consistency across sections. When Module 3 is written as a collection of disconnected documents, even good data becomes difficult to assess.
Thinking in terms of a coherent “quality narrative” is one of the most effective ways to improve Module 3.
The most efficient writing sequence follows data logic, not CTD numbering. E.g. Pharmaceutical Development at the beginning of Module 3 (3.2.P.2.) should be written as summary of decisions, already supported by data. In an iterative model development is finalised after major decisions are stable. It explains why the final strategy makes sense. This section can be repeatedly refined as decisions stabilise, until it becomes coherent justification of the final control strategy.
Rewriting is part of Module 3 development
One of the most common frustrations in Module 3 projects is the sense that sections are “constantly being rewritten.” This is often perceived as inefficiency, poor planning, or a sign that something has gone wrong.
In reality, rewriting is an expected and necessary part of building a robust Module 3.
As the quality elements mature, earlier wording may no longer be accurate, sufficiently justified, or appropriately scoped. Updating the text ensures that Module 3 continues to reflect the current understanding instead of outdated assumptions.
If Module 3 text never changes, it often means decisions are being frozen too early or not challenged at all. Productive rewriting:
- aligns text with newly locked data,
- improves consistency between sections,
- clarifies or strengthens justifications,
- removes unnecessary or overly specific commitments.
This type of rewriting reduces regulatory risk. It is an integral part of quality driven dossier development.
By contrast, re-working usually results from writing too early before data and decisions are sufficiently mature. This leads to late corrections, backtracking, and avoidable internal tension. The problem here is not iteration itself, but poor timing.
This is especially true for:
- pharmaceutical development,
- control strategy descriptions,
- and specification justifications.
These sections often go through several iterations before reaching their final defensible form. That is not a writing problem; it is good regulatory practice.
Start drafting early and update as data evolves
Teams sometimes attempt to minimize need of rewriting by delaying drafting or avoiding clear commitments. Ironically, this usually results in weaker internal alignment and more questions during assessment. Early drafting helps surface unresolved decisions while they are still cheap to fix. Rewriting during development is far less costly than responding to regulatory questions after submission.
When rewriting is seen as a control step rather than a setback, teams collaborate more effectively and dossiers converge more smoothly.
Write Module 3 to support both assessment and post-approval changes
Once approved, the quality dossier becomes the reference point for post-approval quality variations like:
- site changes,
- supplier updates,
- and continuous improvement activities.
Overly detailed Module 3 sections may seem harmless at submission, but they often create unnecessary regulatory commitments later. Conversely, unclear or incomplete data leads to questions, delays, and rework.
Good Module 3 writing balances completeness with restraint – and always considers how the dossier will be used years after approval.
Avoid common Module 3 pitfalls
In practice, Module 3 weaknesses often fall into two categories. Good Module 3 writing is as much about what to leave out as what to include.
1. Missing or outdated elements
These are frequently seen in older or acquired dossiers:
- Insufficient impurity risk assessments
- Outdated validation approaches
- Weak linkage between development data and the registered control strategy
- Inconsistencies between batch data and manufacturing process description
- Insufficient scientific justifications: “Data present but not justified”
These gaps often surface late – during assessment or inspection – when fixing them is most costly.
2. Too much information
At the other extreme, Module 3 can be overloaded with:
- extensive supportive stability data,
- overly detailed manufacturing equipment descriptions,
- unnecessary supplier or material detail.
This does not make the dossier stronger. It makes it harder to assess and harder to maintain.
Typical examples include excessive supportive stability data, overly detailed manufacturing equipment descriptions, or too specific supplier information that does not need to be registered.
Account for regional expectations
The Common Technical Document was created to harmonise regulatory submissions across ICH regions. In practice, a “one size fits all” mindset rarely works. Successful Module 3 strategies recognise regional differences early.
While this article focuses on Module 3 writing from an EU perspective, it is important to recognise that assessment emphasis differs between regions. For example FDA assessments tend to identify technical and data alignment weaknesses, rather than narrative or structural issues.
One clear example of a regional difference is sterile products. Here, EU and US assessment practices diverge most visibly. In the United States, FDA routinely expects more detailed GMP related information to be included directly in Module 3, not only verified through inspections. FDA presentations repeatedly cite major deficiencies related to missing or insufficient sterilisation validation, inadequate validation of aseptic processing equipment and components, weak demonstration of microbiological control for sterile and multidose products, and absence of antimicrobial effectiveness testing where applicable.
For companies used to EU submissions where GMP compliance is largely confirmed through inspections rather than dossier depth, this difference is important to recognise when preparing US facing Module 3 content.
On the other hand, third large ICH region Japan applies the ICH structure with its own assessment dynamics and emphasis on summary driven review. Working closely with a local regulatory CMC expert is key to navigating Japan’s postmarketing commitments and their implications for the quality module. Without this insight, foreign manufacturers may underestimate PMDA specific requirements that go beyond those seen in other regions.
Use gap analysis to identify issues before submission
One of the most effective ways to improve Module 3 is to perform a focused Module 3 gap evaluation before submission or when taking over an existing dossier. Such evaluation helps to identify weaknesses before submission.
A well-designed gap evaluation does not only check for missing documents. It assesses whether:
- The control strategy is clearly described and justified
- Information is placed in the right sections and at the right level
- The dossier reflects current regulatory expectations
- The content supports future changes without reopening core discussions
Seen this way, gap evaluations are quality-driven design tools.
Prepare Module 3 for ICH M4Q(R2) changes
The revision of ICH M4Q(R2) marks a decisive shift in how the CTD quality content is structured and used. Going forward, Module 3 is increasingly expected to function as the structured, authoritative source of quality data, while Module 2.3 (Quality Overall Summary) takes on a more central role in explaining, integrating, and contextualizing that data.
Under M4Q(R2), Module 3 is no longer the place for extensive narrative explanations or repeated justifications. Its role is to present complete, consistent, and well‑structured data that clearly defines what is registered and controlled.
At the same time, Module 2.3 becomes the primary place where the quality story is told:
- how the data in Module 3 fits together,
- how risks are understood and controlled,
- and how the overall control strategy is justified.
This clearer separation means that explanations, rationales, and overarching logic should increasingly sit in Module 2 – not scattered across Module 3 sections.
As a result, good Module 3 writing is no longer about telling the story repeatedly in different places. It is about providing high quality data that can be confidently summarised and interpreted elsewhere.
For more information about Module 3, read our Q&A answering the common questions.
Module 3 writing is a strategic activity that directly affects approval timelines, regulatory burden and the long-term value of a marketing authorisation.
Medfiles supports the preparation and maintenance of Module 3 as part of the full marketing authorisation dossier. Our CMC and regulatory experts help ensure that quality data, control strategy and the overall application are aligned and meet current regulatory expectations. In addition, Medfiles CMC performs gap analyses for existing Module 3 dossiers, helping to identify missing, outdated or misaligned content.
We work across the lifecycle, from early development and dossier preparation to updates and responses during assessment, helping to keep your documentation clear, consistent and maintainable – whether you need support for individual tasks or fully outsourced solutions.
Author: Eeva-Maija Walin, Senior Pharmaceutical Chemical Expert
Eeva-Maija Walin has worked at Medfiles since 2019 as a Senior Pharmaceutical Chemical (CMC) Expert. She holds an M.Sc. in Chemistry and has further broadened her expertise through studies in pharmacy and microbiology at open universities. Prior to joining Medfiles, Eeva-Maija worked for almost 20 years in various CMC expert roles within the pharmaceutical industry.
She has extensive experience in CMC documentation for new marketing authorisation applications and post-approval variations submitted to EU medicines authorities and the FDA. Her expertise includes preparation of quality summaries, evaluation of client documentation against regulatory requirements (gap analyses), and advising on GMP-related matters. At Medfiles, Eeva-Maija supports clients in a wide range of drug development and lifecycle management projects for both human and veterinary medicinal products, drawing on her strong background in pharmaceutical development, quality documentation and regulatory compliance.
